Letter from the Cancer Center Director
Thank you for your interest in the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer
Center, a premier cancer and research treatment center at the University of
Maryland, Baltimore. The cancer center is a joint program of the University of Maryland School of Medicine and the University of Maryland Medical System. In 2016, UMGCCC was named a National Cancer Institute (NCI)-designated comprehensive cancer center, one of fewer than 50 such centers in the country.
At UMGCCC, we pride ourselves in providing outstanding patient care, with an
emphasis on the multidisciplinary approach to diagnosis and treatment. Teams
consisting of medical oncologists, surgeons, radiation oncologists, pathologists,
radiologists, nurses and others work together to bring compassionate and cutting-edge
care to our patients.
Activities of the cancer center include basic and translational cancer research, student and house officer teaching, and a strong focus on new therapies in both an inpatient 46-bed unit and an outpatient setting, the Roslyn and Leonard Stoler Pavilion.
research is a top priority, with scientists working together with clinicians to facilitate
the translation of scientific discoveries into clinical advances. One outstanding example of
the research at UMGCCC is the work of Dr.
Angela Brodie who developed the first aromatase inhibitor here at Maryland. These drugs
have been the most important recent advance in the treatment of breast cancer, dramatically
improving outcomes for women worldwide. Dr. Brodie has been honored for this pioneering work by the
prestigious Kettering and Landon prizes.
Cancer research funding at UMGCCC has grown more than threefold since 2002 — from $19.4 to $61.7 million, continuing to drive scientific discovery by our cancer experts, all of whom are on the faculty of the University of Maryland School of Medicine. The center is a strong participant in new drug development and trials, and is a member of several national cooperative groups.
We have strong translational research programs in experimental therapeutics, hormone responsive cancers, molecular and structural biology, tumor immunology and immunotherapy, and population science. UMGCCC is a leader in addressing cancer disparities, with research focused on improving access to care and treatment outcomes for minorities, who represent 34 percent of the patients in our clinical trials, compared to less than 2 percent nationally.
We think this environment is an exceptional place for fellowship training.
At UMGCCC, we offer the combination of a robust array of clinical
trials, dedicated clinician-educators and cutting-edge basic science
researchers in state-of-the-art facilities, making our institution an outstanding place
Again, thank you for your interest in our institution, and we look forward to your
Kevin J. Cullen, M.D.
Marlene and Stewart Greenebaum Distinguished Professor of Oncology
University of Maryland Greenebaum Comprehensive Cancer Center